PBPK Modeling Patents: Who Leads, Where the Gaps Are 2026
Physiologically Based Pharmacokinetic Modeling Patents
68.5% concentration. The top 5 assignees account for 98 of the 143 records in scope — filing here is concentrated, not fragmented. Filings rose from 2 in 2017 to a peak of 42 in 2022, then continued at a comparable pace through 2024 (18 to 21, +17% over that span). 2025 and 2026 are undercounted because publication typically lags filing by around 18 months.
- 1TAKEDA PHARMA CO LTD38
- 2GLOBAL BLOOD THERAPEUTICS INC24
- 3MYOKARDIA INC15
- 4GENZYME CORP13
- 5CHUGAI PHARMA CO LTD8
See the full physiologically based pharmacokinetic modeling analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about PBPK modeling patents
Who holds the most PBPK modeling patents?
One assignee leads with 38 of the 143 records in this dataset, well ahead of the fifth-place holder at 8. The top 5 assignees combine for 68.5% of all records, and the top 10 reach 86.0%, so the field is concentrated among a small group rather than evenly spread. Anyone entering this space should expect to negotiate around a small number of dominant portfolios rather than many small ones.
Is PBPK modeling patent activity still growing?
Filings grew from 18 in 2021 to 21 in 2024, a 17% increase over that span, after peaking at 42 in 2022. Numbers for 2025 and 2026 in this dataset are not yet reliable indicators of a slowdown because patent publication typically lags actual filing by around 18 months. The last fully comparable years show sustained rather than declining activity.
What technology areas do PBPK patents mostly fall under?
The two largest IPC subclasses are A61K (medicinal preparations), covering 76.2% of the 143 records, and A61P (therapeutic activity of compounds) at 62.2%. Smaller but distinct clusters exist in G01N (material analysis and testing) at 9.1% and computational chemistry class G16C at 7.7%. This means most claims are tied to a specific drug composition or indication rather than being generic modeling-method claims.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Physiologically Based Pharmacokinetic Modeling covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.